2016). In particular, dimeric PKM2 was shown to translocate into the nucleus to activate STAT3 in CD4+T cells, macrophages, and cancer cells (Ma et al. 2019; Damasceno et al. 2020; Hou et al. 2020). However, the potential mechanisms of PKM2 in T cell activation and differentiation remain unclear. Recent studies reported that inducing PKM2 tetramerization and blocking its nuclear translocation could strongly inhibit CD4+T cell activation and pathogenicity (Angiari et al. 2020), and the expression of PKM2 is associated with Th17 cell differentiation (Seki et al. 2020). This evidence concerns the gene CD4 and cancer.